Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1

Human Molecular Genetics

Volumn 17, Issue 14, 2008, Pages 2108-2117

  Catoire, Hélène ^a,b   Pasco, Matthieu Y ^a,b,c   Abu Baker, Aida ^c   Holbert, Sébastien ^a,b   Tourette, Cendrine ^a,b   Brais, Bernard ^c   Rouleau, Guy A ^c   Parker, J Alex ^a,b   Néri, Christian ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE INHIBITOR; MUTANT PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; POLYADENYLIC ACID BINDING PROTEIN; PROTEIN INHIBITOR; RESVERATROL; SIRTINOL; SIRTUIN; SIRTUIN 2 INHIBITOR; TRANSCRIPTION FACTOR DAF 16; TRANSCRIPTION FACTOR FOXO;

ANIMAL CELL; ARTICLE; CELL METABOLISM; CELL MOTILITY; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME INHIBITION; LONGEVITY; MAMMAL CELL; MUSCLE ATROPHY; MUSCLE CELL; NEMATODE; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING;

ACETYLATION; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BENZAMIDES; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COS CELLS; GENE EXPRESSION REGULATION; GENES, REPORTER; HISTONES; HUMANS; MULTIENZYME COMPLEXES; MUSCLES; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; NAPHTHOLS; PEPTIDE INITIATION FACTORS; PEPTIDES; PROTEIN-SERINE-THREONINE KINASES; RNA-BINDING PROTEINS; SIRTUINS; STILBENES; TRANSCRIPTION FACTORS;

MAMMALIA; NEMATODA;

EID: 46249124837     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn109     Document Type: Article

References (54)

1. Brais, B. (2003) Oculopharyngeal muscular dystropby: A late-onset polyalanine disease. Cytogenet.Genome Res., 100, 252-260.
2. Brais, B., Bouchard, J.P., Xie, Y.G., Rochefort, D.L., Chretion, N., Tome, F.M., Lafreniere, R.G., Rommens, J.M., Uyama, E., Nohira, O. et al. (1998) Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. [Erratum (1998) Nat Genet, 19, 404.] Nat. Genet., 18, 164-167.
3. Keller, R.W., Kuhn, U.,Aragon, M., Bornikova, L., Wahle, E. and Bear, D.G. (2000) The nuclear poly(A) binding protein; PABP2, forms an oligomeric particle covering the length of the poly(A) tail. J Mol Biol. 297, 569-583.
4. Calado, A., Kutay, U., Kuhn, U., Wahle, E. and Carmo-Fonseca, M. (2000) Deciphering the cellular pathway for transport of poly(A)-binding protein II. Rna, 6, 245-256.
5. Kim, Y.J., Noguchi, S., Hayashi, Y.K., Tsukahara, T., Shimizu, T. and Arahata, K. (2001) The product of an oculopharyngeal muscular dystrophy gene, poly(A)- binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. Hum. Mol. Genet., 10, 1129-1139.
6. Becher, M.W., Kotzuk, J.A., Davis, L.E. and Bear, D.G. (2000) Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(A) binding protein 2. Ann. Neurol., 48, 812-815.
7. Hino, H., Araki, K., Uyama, E., Takeya, M., Araki, M., Yoshinobu, K., Miike, K., Kawazoe, Y., Maeda, Y., Uchino, M. et al. (2004) Myopathy phenotype in transgenic mice expressing mutated PABPNi as a model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet., 13, 181-190.
8. Bao, Y.P., Cook, L.J., O'Donovan, D., Uyama, E. and Rubinsztein, D.C. (2002) Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J. Biol. Chem., 277, 12263-12269.
9. Abu-Baker, A., Messaed, C., Laganiere, J., Gaspar, C., Brais, B. and Rouleau, G.A. (2003) Involvement of the ubiquitin-proteasome pathway and molecular chaperones oculopharyngeal muscular dystrophy. Hum. Mol. Genet., 12, 2609-2623.
10. Berciano, M.T., Villagra, N.T., Ojeda, J.L., Navascues, J., Gomes, A., Lafarga, M. and Carmo-Fonseca, M. (2004) Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus. Hum. Mol. Genet., 13, 829-838.
11. Tavanez, J.P., Calado, P., Braga, J., Lafarga, M. and Carmo-Fonseca, M. (2005) In Vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1. Rna, 11, 752-762.
12. Messaed, C., Dion, P., Abu-Baker, A., Rochefort, D., Laganiere, J., Brais, B. and rouleau, G.A. Q007) Soluble expanded PABPN1 promotes cell death in Oculopharyngeal muscular dystrophy. Neurobiol. Dis., 26, 546-557.
13. Calado, A., Tome, F.M., Brais, B., Rouleau, G.A., Kuhn, U., Wahle, E. and Carmo-Fonseca, M. (2000) Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum. Mol. Genet., 9, 2321-2328.
14. Corbeil-Girard, L.P., Klein, A.F., Sasseville, A.M., Lavoie, H., Dicaire, M.J., Saint-Denis, A., Page, M., Duranceau, A., Codere. F., Bouchard, J.P. et al. (2005) PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol. Dis., 18, 551-567.
15. Abu-Baker, A. and Rouleau, G.A. (2007) Oculopharyngeal muscular dystrophy: Recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim. Biophys. Acta, 1772, 173-185.
16. Berger, Z., Ravikumar, B., Menzies, F.M., Oroz, L.G., Underwood, B.R., Pangalos, M.N., Schmitt, I., Wullner, U., Evert, B.O., O'Kane, C.J. et al. (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet., 15, 433-442.
17. Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.F., Kwon, H., Yi, S., Mucke, L. and Gan, L. (2005) SIRT1 protects against microglia-dependent beta amyloid toxicity through inhibiting NF-kappa B signaling. J. Biol. Chem., 280, 40364-40374.
18. Cohen, E., Bieschke, J., Perciavalle, R.M., Kelly, J.W. and Dillin, A. (2006) Opposing activities protect against age-onset proteotoxicity. Science, 313, 1604-1610.
19. Parker, J.A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H. and Neri, C. (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet., 37, 349-350.
20. Rubinsztein, D.C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 443, 780-786.
21. Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K. et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337-342.
22. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P. et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122.
23. Dasgupta, B. and Milbrandt, J. (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA, 104, 7217-7222.
24. Okkema, P.G., Harrison, S.W., Plunger, V., Aryana, A. and Fire, A. (1993) Sequence requirements for myosin gene expression and regulation in Caenorhabditis elegans. Genetics, 135, 385-404.
25. Giugia, J., Gieseler, K., Arpagaus, M. and Segalat, L. (1999) Mutations in the dystrophin-like dys-1 gene of Caenorhabditis elegans result in reduced acetylcholinesterase activity. FEBS Lett., 463, 270-272.
26. Kostrouchova, M., Housa, D., Kostrouch, Z., Saudek, V. and Rall, J.E. (2002) SKIP is an indispensable factor for Caenorhabditis elegans development. Proc. Natl. Acad. Sci. USA, 99, 9254-9259.
27. Zhou, S., Fujimuro, M., Hsieh, J.J., Chen, L. and Hayward, S.D. (2000) A role for SKIP in EBNA2 activation of CBF1-repressed promoters. J. Virol., 74, 1939-1947.
28. Minetti, G.C., Colussi, C., Adami, R., Serra, C., Mozzetta, C., Parente, V., Fortuni, S., Straino, S., Sampaolesi, M., Di Padova, M. et al. (2006) Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med., 12, 1147-1150.
29. Riessland, M., Brichta, L., Hahnen, E., and Wirth, B. (2006) The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet., 120, 101-110.
30. Longo, V.D. and Kennedy, B.K. (2006) Sirtuins in aging and age-related disease. Cell, 126, 257-268.
31. Oin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan, M., MacGrogan, D., Rodgers, J.T., et al. (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem, 281, 21745-21754.
32. Tissenbaum, H.A. and Guarente, L. (2001) Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature, 410 227-230.
33. Morley, J.F., Brignull, H.R., Weyers, J.J. and Morimoto, R.I. (2002) The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 99, 10417-10422.
34. Apfeld, J., O'Connor, G., McDonagh, T., DiStefano, P.S. and Curtis, R. (2004) The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev., 18 3004-3009.
35. Greer, E.L., Oskoui, P.R., Banko, M.R., Maniar, J.M., Gygi, M.P., Gygi, S.P. and Brunet, A. (2007) The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem., 282, 30107-30119.
36. Deng, J., Grande, F. and Neamati, N. (2007) Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drug Targets, 7, 91-107.
37. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., Zipkin, R.E., Chung, P., Kisielewski, A., Zhang, L.L. et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425, 191-196.
38. Marambaud, P., Zhao, H. and Davies, P. (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem., 280, 37377-37382.
39. Valenzano, D.R., Terzibasi, E., Genade, T., Cattaneo, A., Domenici, L. and Cellerino, A. (2006) Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 16, 296-300.
40. Bedalov, A., Gatbonton, T., Irvine, W.P., Gottschling, D.E. and Simon, J.A. (2001) Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA, 98, 15113-15118.
41. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. and Finkbeiner, S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 431, 805-810.
42. Bowman, A.B., Lam, Y.C., Jafar-Nejad, P., Chen, H.K., Richman, R., Samaco, R.C., Fryer, J.D., Kahle, J.J., Orr, H.T. and Zoghbi, H.Y. (2007) Duplication of Atxn11 suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat. Genet., 39, 373-379.
43. Araki, T., Sasaki, Y. and Milbrandt, J. (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science, 305, 1010-1013.
44. Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., Amore, A.M., Volk, C.B., Maxwell, M.M., Rochet, J.C., McLean, P.J. et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 317, 516-519.
45. Carter, M.E. and Brunet, A. (2007) FOXO transcription factors. Curr. Biol., 17, R113-R114.
46. Mammucari, C., Schiaffino, S. and Sandri, M. (2008) Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy, 4. ahead of print.
47. Zhao, J., Brault, J.J., Schild, A., Cao, P., Sandri, M., Schiaffino, S., Lecker, S.H. and Goldberg, A.L. (2007) FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab., 6, 472-483.
48. Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S.H. and Goldberg, A.L. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell, 117, 399-412.
49. Allen, D.L. and Unterman, T.G. (2007) Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell Physiol., 292, C188-C199.
50. Waterston, R.H., Hirsh, D. and Lane, T.R. (1984) Dominant mutations affecting muscle structure in Caenorhabditis elegans that map near the actin gene cluster. J. Mol. Biol., 180, 473-496.
51. Berdichevsky, A., Viswanathan, M., Horvitz, H.R. and Guarente, L. (2006) C. elegans SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span. Cell, 125, 1165-1177.
52. Hosoda, N., Lejeune, F. and Maquat, L.E. (2006) Evidence that poly(A) binding protein C1 binds nuclear pre-mRNA poly(A) tails. Mol. Cell. Biol., 26, 3085-3097.
53. Duerr, J.S. (2006) Immunohistochemistry (June 19, 2006). In The C. elegans Research Community (ed.), WormBook. WormBook. doi/ 10.1895/wormbook.1.105.1, http://www.wormbook.org.
54. Yoshida, M., Furumai, R., Nishiyama, M., Komatsu, Y., Nishino, N. and Horinouchi, S. (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol., 48 (Suppl 1), S20-S26.